removab
neovii biotech gmbh - catumaxomab - ascites; cancer - iné antineoplastické látky - removab je indikovaný pri intraperitoneálnej liečbe malígneho ascitu u pacientov s epcam-pozitívnymi karcinómami kde štandardná liečba nie je k dispozícii alebo už nie je možné.
irinotecan kabi 20 mg/ ml infúzny koncentrát
fresenius kabi s.r.o., Česká republika - irinotekán - 44 - cytostatica
irinotecan accord 20 mg/ml koncentrát na infúzny roztok
accord healthcare polska sp. z o.o., poľsko - irinotekán - 44 - cytostatica
irinotecan viatris 20 mg/ ml
viatris limited, Írsko - irinotekán - 44 - cytostatica
trabectedin teva 1 mg prášok na koncentrát na infúzny roztok
teva b.v., holandsko - trabektedín - 44 - cytostatica
trabectedin teva 0,25 mg prášok na koncentrát na infúzny roztok
teva b.v., holandsko - trabektedín - 44 - cytostatica
trabectedin ever pharma 1 mg prášok na koncentrát na infúzny roztok
ever valinject gmbh, rakúsko - trabektedín - 44 - cytostatica
trabectedin ever pharma 0,25 mg prášok na koncentrát na infúzny roztok
ever valinject gmbh, rakúsko - trabektedín - 44 - cytostatica
lonsurf
les laboratoires servier - trifluridine, tipiracil hydrochlorid - kolorektálne novotvary - antineoplastické činidlá - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
dovprela (previously pretomanid fgk)
mylan ire healthcare limited - pretomanid - tuberkulóza, odolná voči viacerým liečivám - antimycobacterials - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní antibakteriálne agentov.